Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myelodysplastic syndromes (MDS) with ring sideroblasts involve iron accumulation in erythroid mitochondria.
• Somatic mutations in splicing machinery are common in these MDS subtypes.
• Current treatments like erythropoiesis-stimulating agents often lack efficacy for sustained anemia improvement.

Purpose of the Study:

• To review activin receptor ligand traps as a novel therapeutic strategy.
• To highlight their potential for sideroblastic myelodysplastic syndromes.
• To discuss their mechanism in promoting erythroid differentiation.

Main Methods:

• Review of current literature on MDS, ring sideroblasts, and TGF-β signaling.
• Analysis of preclinical and clinical data on activin receptor ligand traps.
• Discussion of the role of TGF-β pathway in erythropoiesis.

Main Results:

• Activin receptor ligand traps have demonstrated efficacy in alleviating anemia in preclinical models.
• These agents specifically inhibit aberrant TGF-β signaling pathways.
• The inhibition of TGF-β signaling promotes late-stage erythroid differentiation.

Conclusions:

• Activin receptor ligand traps represent a promising therapeutic avenue for anemia in myelodysplastic syndromes with ring sideroblasts.
• Targeting TGF-β signaling offers a novel approach to overcome treatment resistance.
• Further clinical investigation is warranted to establish their role in patient care.